MX2022000468A - Metodos para aliviar la preocupacion asociada al pterigion sobre el aspecto del ojo. - Google Patents
Metodos para aliviar la preocupacion asociada al pterigion sobre el aspecto del ojo.Info
- Publication number
- MX2022000468A MX2022000468A MX2022000468A MX2022000468A MX2022000468A MX 2022000468 A MX2022000468 A MX 2022000468A MX 2022000468 A MX2022000468 A MX 2022000468A MX 2022000468 A MX2022000468 A MX 2022000468A MX 2022000468 A MX2022000468 A MX 2022000468A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- eye
- pterigion
- alleviate
- concern associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898401P | 2019-09-10 | 2019-09-10 | |
| PCT/US2020/050150 WO2021050692A2 (en) | 2019-09-10 | 2020-09-10 | Methods for alleviating pterygium-associated worry about eye appearance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000468A true MX2022000468A (es) | 2022-02-03 |
Family
ID=74870040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000468A MX2022000468A (es) | 2019-09-10 | 2020-09-10 | Metodos para aliviar la preocupacion asociada al pterigion sobre el aspecto del ojo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220331310A1 (enExample) |
| EP (1) | EP4027997A4 (enExample) |
| JP (2) | JP2022547401A (enExample) |
| KR (1) | KR20220061147A (enExample) |
| CN (1) | CN114340618A (enExample) |
| AU (2) | AU2020346812A1 (enExample) |
| BR (1) | BR112021026662A2 (enExample) |
| CA (1) | CA3146811A1 (enExample) |
| MX (1) | MX2022000468A (enExample) |
| WO (1) | WO2021050692A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| BR112018074450A2 (pt) | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100185564A1 (en) * | 2009-01-21 | 2010-07-22 | Mccormick & Company, Inc. | Method and questionnaire for measuring consumer emotions associated with products |
| WO2013188268A1 (en) * | 2012-06-12 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing pazopanib |
| US8747852B1 (en) * | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
| CN108135737B (zh) * | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| EA035465B1 (ru) * | 2015-06-09 | 2020-06-22 | Байер Фарма Акциенгезельшафт | 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения |
| TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| CN108295072A (zh) * | 2015-12-09 | 2018-07-20 | 瑞阳(苏州)生物科技有限公司 | 尼达尼布防治眼部疾病的用途 |
| MX394623B (es) * | 2016-02-04 | 2025-03-24 | Ads Therapeutics Llc | Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades. |
| BR112018074450A2 (pt) * | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
| US11278546B2 (en) * | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| WO2018064354A1 (en) * | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| JP7306697B2 (ja) * | 2017-03-14 | 2023-07-11 | オールジェネシス バイオセラピューティクス インコーポレイテッド | ３－ｚ－［１－（４－（ｎ－（（４－メチル－ピペラジン－１－イル）－メチルカルボニル）－ｎ－メチル－アミノ）－フェニルアミノ）－１－フェニル－メチレン］－６－メトキシカルボニル－２－インドリノンの結晶形 |
| KR20210013574A (ko) * | 2018-05-25 | 2021-02-04 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법 |
-
2020
- 2020-09-10 BR BR112021026662A patent/BR112021026662A2/pt unknown
- 2020-09-10 EP EP20863255.4A patent/EP4027997A4/en active Pending
- 2020-09-10 MX MX2022000468A patent/MX2022000468A/es unknown
- 2020-09-10 WO PCT/US2020/050150 patent/WO2021050692A2/en not_active Ceased
- 2020-09-10 JP JP2022507861A patent/JP2022547401A/ja active Pending
- 2020-09-10 CA CA3146811A patent/CA3146811A1/en active Pending
- 2020-09-10 AU AU2020346812A patent/AU2020346812A1/en not_active Abandoned
- 2020-09-10 KR KR1020227010256A patent/KR20220061147A/ko active Pending
- 2020-09-10 CN CN202080061833.2A patent/CN114340618A/zh active Pending
- 2020-09-10 US US17/640,889 patent/US20220331310A1/en active Pending
-
2026
- 2026-03-09 JP JP2026036757A patent/JP2026090631A/ja active Pending
- 2026-03-27 AU AU2026202351A patent/AU2026202351A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020346812A1 (en) | 2022-01-27 |
| WO2021050692A3 (en) | 2021-05-14 |
| EP4027997A4 (en) | 2023-10-11 |
| KR20220061147A (ko) | 2022-05-12 |
| WO2021050692A2 (en) | 2021-03-18 |
| AU2026202351A1 (en) | 2026-04-16 |
| US20220331310A1 (en) | 2022-10-20 |
| CA3146811A1 (en) | 2021-03-18 |
| EP4027997A2 (en) | 2022-07-20 |
| BR112021026662A2 (pt) | 2022-04-12 |
| JP2022547401A (ja) | 2022-11-14 |
| JP2026090631A (ja) | 2026-06-02 |
| CN114340618A (zh) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001188A1 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos. | |
| MX2020011401A (es) | Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis. | |
| AR103130A1 (es) | Sonda de vitrectomía con un escáner de fibra óptica | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CO2025011012A2 (es) | Agonistas heterocíclicos de glp-1 | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2019001044A2 (es) | Composición de cannabis | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| MX2017015838A (es) | Composiciones y metodos para tratar pterigion. | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2020000166A1 (es) | Compuestos bifuncionales. | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| MX2020003049A (es) | Semaglutida en la terapia medica. | |
| CL2024002614A1 (es) | Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso. | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| MX368954B (es) | Insectos modificados para reducir la expresion genica especifica en los testiculos para los metodos de control biologico. | |
| MX2020012836A (es) | Batas quirurgicas. | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| DOP2017000014A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
| UY33153A (es) | Formulación tópica oftálmica de péptidos |